Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 2,3,5-Triiodobenzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.44 |
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.39 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.31 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.31 |
| ▸ | TPMT | P51580 | 2/20 | 0.48 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,3,5-Triiodobenzoic Acid SCHEMBL23524593 | 1.00 | TPMT (0.48) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL39041 | 0.98 | TPMT (0.50) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL6397062 | 0.95 | TPMT (0.48) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL31349978 | 0.90 | TPMT (0.43) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL26604178 | 0.85 | TPMT (0.39) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL4264372 | 0.83 | TPMT (0.38) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL9324434 | 0.83 | TPMT (0.38) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| 2,3,5-Triiodobenzoic Acid SCHEMBL28647106 | 0.83 | MAOB (0.41) | TPMTMAOBPTPRCPTPN2PTPN1 | |
| Hydrochloric Acid SCHEMBL23524594 | 0.80 | TTR (0.37) | TPMTMAOBTTRHDAC3HDAC4 | |
| SCHEMBL879358 | 0.79 | TTR (0.46) | TPMTMAOBTTRHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188770-A1 | ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-06-24 | — | — | US | disclosed |
| US-8574550-B2 | Biocompatible polymeric contrast agents and radiopaque materials for medical services | CORDIS CORPORATION | 2013-11-05 | — | — | US | disclosed |
| US-20120252984-A1 | BIOCOMPATIBLE POLYMERIC CONTRAST AGENTS AND RADIOPAQUE MATERIALS FOR MEDICAL SERVICES | CORDIS CORPORATION (US) | 2012-10-04 | — | — | US | disclosed |
| US-8197796-B2 | organic high intensity X-ray contrast agents, dispersed within or conjugated biodegradable polymers, suitable for enhancing the imaging of medical devices, particularly polymeric medical devices and polymeric coatings | CORDIS CORPORATION | 2012-06-12 | — | — | US | disclosed |
| US-7771705-B2 | Radiographic contrasting agents and radio-opaque polymeric materials for medical devices | CORDIS CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-7704488-B2 | Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same | CORDIS CORPORATION (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090209745-A1 | RADIOGRAPHIC CONTRASTING AGENTS AND RADIO-OPAQUE POLYMERIC MATERIALS FOR MEDICAL DEVICES | CORDIS US CORP | 2009-08-20 | — | — | US | disclosed |
| EP-2005971-A1 | Contrast agents for medical devices | Cordis Corporation (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2005972-A1 | Contrast agents for medical devices | Cordis Corporation (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080275210-A1 | BIOCOMPATIBLE POLYMERIC CONTRAST AGENTS AND RADIOPAQUE MATERIALS FOR MEDICAL DEVICES | CORDIS US CORP | 2008-11-06 | — | — | US | disclosed |
| US-20080177102-A1 | DENDRITIC AND STAR-SHAPED CONTRAST AGENTS FOR MEDICAL DEVICES AND BIOABSORBABLE RADIOPAQUE BULK MATERIAL AND METHOD FOR PRODUCING SAME | CORDIS US CORP | 2008-07-24 | — | — | US | disclosed |
| EP-1815871-A2 | Radiographic contrasting agents and radio-opaque polymeric materials for medical devices | Cordis Corporation (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070134163-A1 | Radiographic contrasting agents and radio-opaque polymeric materials for medical devices | CORDIS US CORP | 2007-06-14 | — | — | US | disclosed |
| US-20060292077-A1 | Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same | CORDIS US CORP | 2006-12-28 | — | — | US | disclosed |
| EP-1702628-A2 | Contrast agents for medical devices | Cordis Corporation (US) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177102-A1 | DENDRITIC AND STAR-SHAPED CONTRAST AGENTS FOR MEDICAL DEVICES AND BIOABSORBABLE RADIOPAQUE BULK MATERIAL AND METHOD FOR PRODUCING SAME | MSR1, MYD88, CD209 | MAOB 3661/4885TTR 4695/4885HDAC3 3543/4885 |
| US-20210188770-A1 | ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SLC6A5, LIFR, SLC6A9 | MAOB 3888/4885TTR 4845/4885HDAC3 3525/4885 |
| US-20090209745-A1 | RADIOGRAPHIC CONTRASTING AGENTS AND RADIO-OPAQUE POLYMERIC MATERIALS FOR MEDICAL DEVICES | MYADM, PBRM1, RXFP3 | MAOB 1517/4885TTR 2900/4885HDAC3 1323/4885 |
| US-20070134163-A1 | Radiographic contrasting agents and radio-opaque polymeric materials for medical devices | MYADM, PBRM1, RXFP3 | MAOB 1517/4885TTR 2900/4885HDAC3 1323/4885 |
| US-20120252984-A1 | BIOCOMPATIBLE POLYMERIC CONTRAST AGENTS AND RADIOPAQUE MATERIALS FOR MEDICAL SERVICES | CD68, PBRM1, TLR9 | MAOB 3228/4885TTR 4188/4885HDAC3 1162/4885 |
| US-20080275210-A1 | BIOCOMPATIBLE POLYMERIC CONTRAST AGENTS AND RADIOPAQUE MATERIALS FOR MEDICAL DEVICES | CD68, TLR9, PBRM1 | MAOB 3367/4885TTR 4506/4885HDAC3 1207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.